Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints.

PURPOSE To evaluate and quantify visual function metrics to be used as endpoints of age-related macular degeneration (AMD) stages and visual acuity (VA) loss in patients with early and intermediate AMD. DESIGN Cross-sectional analysis of baseline data from a prospective study. METHODS One hundred and one patients were enrolled at Duke Eye Center: 80 patients with early AMD (Age-Related Eye Disease Study [AREDS] stage 2 [n = 33] and intermediate stage 3 [n = 47]) and 21 age-matched, normal controls. A dilated retinal examination, macular pigment optical density measurements, and several functional assessments (best-corrected visual acuity, macular integrity assessment mesopic microperimety, dark adaptometry, low-luminance visual acuity [LLVA] [standard using a log 2.0 neutral density filter and computerized method], and cone contrast test [CCT]) were performed. Low-luminance deficit (LLD) was defined as the difference in numbers of letters read at standard vs low luminance. Group comparisons were performed to evaluate differences between the control and the early and intermediate AMD groups using 2-sided significance tests. RESULTS Functional measures that significantly distinguished between normal and intermediate AMD were standard and computerized (0.5 cd/m2) LLVA, percent reduced threshold and average threshold on microperimetry, CCTs, and rod intercept on dark adaptation (P < .05). The intermediate group demonstrated deficits in microperimetry reduced threshhold, computerized LLD2, and dark adaptation (P < .05) relative to early AMD. CONCLUSIONS Our study suggests that LLVA, microperimetry, CCT, and dark adaptation may serve as functional measures differentiating early-to-intermediate stages of dry AMD.

[1]  R. Hays,et al.  Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators , 1998 .

[2]  Ivana K. Kim,et al.  Diagnostic sensitivity and specificity of dark adaptometry for detection of age-related macular degeneration. , 2014, Investigative ophthalmology & visual science.

[3]  M. Wintergerst,et al.  Association of Vision-related Quality of Life with Visual Function in Age-Related Macular Degeneration , 2019, Scientific Reports.

[4]  U. Schmidt-Erfurth,et al.  Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study. , 2015, American journal of ophthalmology.

[5]  A. Althouse Adjust for Multiple Comparisons? It's Not That Simple. , 2016, The Annals of thoracic surgery.

[6]  C. Mangione,et al.  Influence of age-related maculopathy on visual functioning and health-related quality of life. , 1999, American journal of ophthalmology.

[7]  L. Ayton,et al.  Low-luminance visual acuity and microperimetry in age-related macular degeneration. , 2014, Ophthalmology.

[8]  L. Ayton,et al.  Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration. , 2015, JAMA ophthalmology.

[9]  Jennifer H. Acton,et al.  Microperimetry in Age-Related Macular Degeneration: An Evidence-Base for Pattern Deviation Probability Analysis in Microperimetry , 2019, Translational vision science & technology.

[10]  Jeff Rabin,et al.  Rapid quantification of color vision: the cone contrast test. , 2011, Investigative ophthalmology & visual science.

[11]  D M Snodderly,et al.  Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. , 1995, The American journal of clinical nutrition.

[12]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[13]  Christine A. Curcio,et al.  The spatial resolution capacity of human foveal retina , 1989, Vision Research.

[14]  N. Notaroberto,et al.  Detection of Macular Function Changes in Early (AREDS 2) and Intermediate (AREDS 3) Age-Related Macular Degeneration , 2010, Ophthalmologica.

[15]  Usha Chakravarthy,et al.  Clinical classification of age-related macular degeneration. , 2013, Ophthalmology.

[16]  Weng Tao,et al.  Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. , 2012, Investigative ophthalmology & visual science.

[17]  Kang Zhang,et al.  Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. , 2014, Ophthalmology.

[18]  Gary S Rubin,et al.  Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. , 2008, Ophthalmology.

[19]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[20]  Peter K Kaiser,et al.  Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). , 2009, Transactions of the American Ophthalmological Society.

[21]  K J Rothman,et al.  No Adjustments Are Needed for Multiple Comparisons , 1990, Epidemiology.

[22]  Cynthia Owsley,et al.  Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy. , 2006, Investigative ophthalmology & visual science.

[23]  M. J. Perez-Carrasco,et al.  Impaired mesopic visual acuity in eyes with early age-related macular degeneration. , 2012, Investigative ophthalmology & visual science.

[24]  K. Rothman Six Persistent Research Misconceptions , 2014, Journal of general internal medicine.

[25]  Lyndon da Cruz,et al.  Development of human embryonic stem cell therapies for age-related macular degeneration , 2013, Trends in Neurosciences.

[26]  David I W Phillips,et al.  Lutein and zeaxanthin status and risk of age-related macular degeneration. , 2003, Investigative ophthalmology & visual science.

[27]  Cynthia Owsley,et al.  Cone- and rod-mediated dark adaptation impairment in age-related maculopathy. , 2007, Ophthalmology.

[28]  T. Sarna,et al.  Zeaxanthin in combination with ascorbic acid or alpha-tocopherol protects ARPE-19 cells against photosensitized peroxidation of lipids. , 2004, Free radical biology & medicine.

[29]  R. Raman,et al.  Association of macular pigment optical density with risk factors for wet age-related macular degeneration in the Indian population , 2012, Eye.

[30]  M. Varano,et al.  MACULAR FUNCTION IN EYES WITH EARLY AGE-RELATED MACULAR DEGENERATION WITH OR WITHOUT CONTRALATERAL LATE AGE-RELATED MACULAR DEGENERATION , 2007, Retina.

[31]  Stefanie G. Schuman,et al.  VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION , 2016, Retina.

[32]  Cynthia Owsley,et al.  Early age-related maculopathy and self-reported visual difficulty in daily life. , 2002, Ophthalmology.

[33]  Richard A. Bone,et al.  Optical density spectra of the macular pigmentin vivo andin vitro , 1992, Vision Research.

[34]  Ningli Wang,et al.  Measurement of macular pigment optical density among healthy Chinese people and patients with early-stage age-related macular degeneration. , 2015, International journal of ophthalmology.

[35]  G. R. Jackson,et al.  Comparison of Visual Function in Older Eyes in the Earliest Stages of Age-related Macular Degeneration to Those in Normal Macular Health , 2016, Current eye research.

[36]  R. Klein,et al.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. , 2014, The Lancet. Global health.

[37]  S. Beatty,et al.  Concordance of macular pigment measurements obtained using customized heterochromatic flicker photometry, dual-wavelength autofluorescence, and single-wavelength reflectance. , 2013, Experimental eye research.

[38]  J. Sahel,et al.  RANDOMIZED CLINICAL TRIAL FRANCE DMLA2: Effect of Trimetazidine on Exudative and Nonexudative Age-RelatedMacular Degeneration , 2012, Retina.

[39]  Sotiris Plainis,et al.  Assessment of macular pigment optical density (MPOD) in patients with unilateral wet age‐related macular degeneration (AMD) , 2011, Acta ophthalmologica.

[40]  A. Bird,et al.  Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. , 2004, Investigative ophthalmology & visual science.

[41]  E. Ghafar-Zadeh,et al.  Recent Advances of Computerized Graphical Methods for the Detection and Progress Assessment of Visual Distortion Caused by Macular Disorders , 2019, Vision.

[42]  P. Bernstein,et al.  Studies on the singlet oxygen scavenging mechanism of human macular pigment. , 2007, Archives of biochemistry and biophysics.